

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Yestar Healthcare Holdings Company Limited**

**巨星醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2393)**

### **INSIDE INFORMATION UPDATE ON PROFIT GUARANTEE IN RELATION TO ACQUISITION OF 70% EQUITY INTEREST IN GUANGZHOU SHENGSHIYUAN TRADING COMPANY LIMITED**

This announcement is made by Yestar Healthcare Holdings Company Limited (the “Company”, together with its subsidiaries, the “Group”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 11 November 2016 (the “Announcement”) in respect of, amongst other things, the acquisition of 70% equity interests in Guangzhou Shengshiyuan Trading Company Limited (“Shengshiyuan”) and announcements of the Company dated 14 June 2023 and 6 March 2024 (the “Arbitration Announcements”) in relation to arbitration from vendors of Shengshiyuan against the Company (the “First Arbitration”). Unless otherwise stated herein, capitalized terms used herein shall have the same meanings as those defined in the Announcement and Arbitration Announcements.

Apart from First Arbitration previously disclosed, another vendor of the Shengshiyuan holding 3% equity interest of Shengshiyuan requested the Company to acquire his related equity interest in the 30% equity interest of Shengshiyuan at a consideration of about RMB11,270,000, calculated according to a 10 times price to 2019 Net Profit (being RMB37,570,000), and demanded for liquidated damage from the Company for not honoring the Share Transfer Agreement to acquire the Remaining Interest.

The Group has recently received a notice (the “Second Arbitration”) from Shanghai International Economic and Trade Arbitration Commission (Shanghai International Arbitration Centre) (the “Arbitration Centre”) for the commencement of arbitration procedure against the Company. The Company has sought legal representative and will submit relevant statements of fact as well as defence documents to the Arbitration Centre before the prescribed deadline.

The Company will keep the shareholders and potential investors of the Company informed of any further significant development in relation to the progress of the Second Arbitration as well as the final decision of revocation of verdict results concluded on 28 February 2024 in relation to the First Arbitration as and when appropriate.

**Shareholders of the Company and the public are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Yestar Healthcare Holdings Company Limited**  
**Liao Changxiang**  
*CEO and executive Director*

Hong Kong, 8 April 2024

*As at the date of this announcement, the executive Directors are Ms. Liao Changxiang and Ms. Wang Hong; the non-executive Director is Mr. Hartono James; and the independent non-executive Directors are Mr. Zeng Jinsong, Mr. Zhao Ziwei and Koeswondo Michael David.*